Please login to the form below

Not currently logged in
Email:
Password:

Istodax

This page shows the latest Istodax news and features for those working in and with pharma, biotech and healthcare.

Novartis gets OK for panobinostat in myeloma

Novartis gets OK for panobinostat in myeloma

followed three years later by Celgene's rival CTCL therapy Istodax (romidepsin). .

Latest news

  • Celgene's cancer drug promising in small HIV study Celgene's cancer drug promising in small HIV study

    Lymphoma therapy Istodax shows potential in treating the virus. A cancer drug sold by Celgene could be used to drive HIV from hidden reservoirs within the body so the virus becomes ... Study leader Ole Schmeltz Søgaard from Aarhus University in Denmark

  • FDA gives early green light to Spectrum’s lymphoma drug FDA gives early green light to Spectrum’s lymphoma drug

    Spectrum's Folotyn anti-folate drug (pralatrexate) was cleared in 2009 for use in patients with relapsed or refractory PTCL while Celgene got the nod for its HDAC inhibitor Istodax (romidepsin) ... Spectrum claims Beleodaq has a broader mechanism than

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics